Last reviewed · How we verify
Nafamostat Mesilate
Nafamostat mesilate is a serine protease inhibitor that blocks multiple coagulation and inflammatory proteases to prevent thrombosis and inflammation.
Nafamostat mesilate is a serine protease inhibitor that blocks multiple coagulation and inflammatory proteases to prevent thrombosis and reduce inflammation. Used for Anticoagulation during hemodialysis and extracorporeal circulation, Acute pancreatitis, Disseminated intravascular coagulation (DIC).
At a glance
| Generic name | Nafamostat Mesilate |
|---|---|
| Also known as | Futhan, no alternative name. Commercial brands are available., CKD-314 |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Serine protease inhibitor |
| Target | Serine proteases (thrombin, factor Xa, kallikrein, trypsin) |
| Modality | Small molecule |
| Therapeutic area | Anticoagulation / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
Nafamostat inhibits serine proteases including thrombin, factor Xa, and kallikrein, thereby suppressing the intrinsic coagulation cascade and contact system activation. It is used primarily as an anticoagulant during hemodialysis and extracorporeal circulation procedures, and has been investigated for its anti-inflammatory and antiviral properties in conditions such as acute pancreatitis and severe respiratory infections.
Approved indications
- Anticoagulation during hemodialysis and extracorporeal circulation
- Acute pancreatitis
- Severe COVID-19 (investigational)
Common side effects
- Bleeding
- Hyperkalemia
- Thrombocytopenia
Key clinical trials
- Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU) (PHASE2)
- Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) (PHASE1)
- Nafamostat Efficacy in Phase 3 Registrational CRRT Study (NA)
- Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO (NA)
- DEFINE - Evaluating Therapies for COVID-19 (PHASE1, PHASE2)
- The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration (NA)
- A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation (NA)
- Oral Nafamostat in Healthy Volunteers (NAF-101) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nafamostat Mesilate CI brief — competitive landscape report
- Nafamostat Mesilate updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI